'Br j haematol' presentation slideshows

Meeting in a Box

1.21k views • 104 slides

B-CLL

B-CLL. DIAGNOSIS PROGNOSIS CLINICAL MANAGEMENT MRD MONITORING THERAPY. CLL Therapy General Considerations. Treat only patients with symptomatic or progressive disease Treatment based on biological factors not justified Include patients in trials whenever possible

884 views • 60 slides

797 views • 54 slides

Pharmacokinetic and Pharmacodynamic Considerations in the Development of Macromolecules

Pharmacokinetic and Pharmacodynamic Considerations in the Development of Macromolecules. Pamela D. Garzone, Ph.D. OUTLINE OF LECTURE TOPICS. Macromolecules Interspecies Scaling Pharmacokinetic Characteristics Scientific Issues Pharmacodynamics Monoclonal Antibodies.

922 views • 51 slides

Thin Blood

Thin Blood. Department of Clinical Toxicology and Pharmacology Newcastle Mater Hospital. Case 1. 37 year old male Presented to JHH Emergency Department Drug overdose 120 mg warfarin Activated charcoal Bloods sent Transfer to MMH after d/w Toxicology. Background.

601 views • 49 slides

Pulmonary Complications of Sickle Cell Disease

Pulmonary Complications of Sickle Cell Disease. Kenneth I. Ataga, MD Comprehensive Sickle Cell Program University of North Carolina - Chapel Hill. Introduction. Sickle hemoglobin (Hb S) occurs when the normal ? 6 glutamic acid residue is replaced by valine

593 views • 45 slides

Part III

607 views • 45 slides

Bor-Sheng Ko ( ??? ), M.D. BMT Unit and Hematology Division Department of Internal Medicine

Bor-Sheng Ko ( ??? ), M.D. BMT Unit and Hematology Division Department of Internal Medicine National Taiwan University Hospital. Prevention and M anagement of G raft-versus-host D isease ( GvHD ) and Tumor Relapse ???????????????????. Outlines. GvHD Definition and Pathogenesis

709 views • 44 slides

Bleeding with antiplatelet agents

Bleeding with antiplatelet agents. Giuseppe Biondi-Zoccai , MD Sapienza University of Rome , Italy giuseppe.biondizoccai@uniroma1.it. Learning goals. Scope of the problem Definitions Pragmatic approach to bleeding Specific recommendations. Learning goals. Scope of the problem

543 views • 42 slides

Update on Novel Combinations for Relapsed/Refractory Disease: Approved Drugs

Update on Novel Combinations for Relapsed/Refractory Disease: Approved Drugs. James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA. Treatment Choices. Anthracyclines Doxorubicin PLD . Thal. Carfilzomib. Bortezomib.

542 views • 39 slides

Background (1)

247 views • 16 slides

DTP Assignment Case # 3 H ematology

285 views • 15 slides

Dose Titration in a Paediatric Patient with Sickle Cell Disease

Dose Titration in a Paediatric Patient with Sickle Cell Disease. Background. There is a significant correlation between the number of transfusions a patient receives and the degree of iron overload in sickle cell disease (SCD) that is reflected in organ failure 1

267 views • 11 slides

Interim Results from Two Phase 2 Clinical Trials in Adults with Beta-Thalassemia

Interim Results from Two Phase 2 Clinical Trials in Adults with Beta-Thalassemia Ellis Neufeld, MD PhD. Data adapted from presentations at 19 th European Hematology Congress in Milan, Italy June 14, 2014. Studies supported by Acceleron Pharma and Celgene. Disclosure for Dr. Neufeld.

372 views • 10 slides

Purroy N et al. Proc ASH 2011;Abstract 593.

Dose-Adjusted EPOCH plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell Lymphoma, with Analysis of Germinal Center and Activated B-Cell Biomarkers. Purroy N et al. Proc ASH 2011;Abstract 593. Background.

237 views • 9 slides